Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 747 results
Found 747 results.

2017

Verma A, Bradford Y, Verma SS, et al. "Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202." Pharmacogenet. Genomics. 2017;27(3):101-111.
Dittmer DP, Tamburro K, Chen H, et al. "Oral shedding of herpesviruses in HIV-infected patients with varying degrees of immune status." AIDS. 2017;31(15):2077-2084.
Gulick RM, Wilkin TJ, Chen YQ, et al. "Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305)." J. Infect. Dis.. 2017;215(2):238-246.
Sherman KE, Kang M, Sterling R, et al. "Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection." World J Hepatol. 2017;9(4):217-223.
Mollan KR, Tierney C, Hellwege JN, et al. "Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants." J. Infect. Dis.. 2017;216(5):554-564.
Yin MT, Chan ES, Brown TT, et al. "Racial differences in calculated bioavailable vitamin D with vitamin D/calcium supplementation." AIDS. 2017;31(17):2337-2344.
O'Brien MP, Hunt PW, Kitch DW, et al. "A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy." Open Forum Infect Dis. 2017;4(1):ofw278.
Currier JS, Britto P, Hoffman RM, et al. "Randomized trial of stopping or continuing ART among postpartum women with pre-ART CD4 ≥ 400 cells/mm3." PLoS ONE. 2017;12(5):e0176009.
Bisson GP, Ramchandani R, Miyahara S, et al. "Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adults." AIDS. 2017;31(16):2217-2225.
Gulick RM, Wilkin TJ, Chen YQ, et al. "Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial." Ann. Intern. Med.. 2017;167(6):384-393.
Naggie S, Marks KM, Hughes M, et al. "Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C." Clin. Infect. Dis.. 2017;64(8):1035-1042.
Thomas AS, Jones KL, Gandhi RT, et al. "T-cell responses targeting HIV Nef uniquely correlate with infected cell frequencies after long-term antiretroviral therapy." PLoS Pathog.. 2017;13(9):e1006629.
Mukherjee PK, Chen H, Patton LL, et al. "Topical gentian violet compared with nystatin oral suspension for the treatment of oropharyngeal candidiasis in HIV-1-infected participants." AIDS. 2017;31(1):81-88.
Funderburg NT, Xu D, Playford MP, et al. "Treatment of HIV infection with a raltegravir-based regimen increases LDL levels, but improves HDL cholesterol efflux capacity." Antivir. Ther. (Lond.). 2017;22(1):71-75.
E Cardozo F, Andrade A, Mellors JW, Kuritzkes DR, Perelson AS, Ribeiro RM. "Treatment with integrase inhibitor suggests a new interpretation of HIV RNA decay curves that reveals a subset of cells with slow integration." PLoS Pathog.. 2017;13(7):e1006478.
Tenforde MW, Yadav A, Dowdy DW, et al. "Vitamin A and D Deficiencies Associated With Incident Tuberculosis in HIV-Infected Patients Initiating Antiretroviral Therapy in Multinational Case-Cohort Study." J. Acquir. Immune Defic. Syndr.. 2017;75(3):e71-e79.
Muhammad J, Chan ES, Brown TT, et al. "Vitamin D Supplementation Does Not Affect Metabolic Changes Seen With ART Initiation." Open Forum Infect Dis. 2017;4(4):ofx210.

2016

Cohen MS, Chen YQ, McCauley M, et al. "Antiretroviral Therapy for the Prevention of HIV-1 Transmission." N. Engl. J. Med.. 2016;375(9):830-9.
De Boni RB, Zheng L, Rosenkranz SL, et al. "Binge drinking is associated with differences in weekday and weekend adherence in HIV-infected individuals." Drug Alcohol Depend. 2016;159:174-80.
McComsey GA, Moser C, Currier J, et al. "Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s." Clin. Infect. Dis.. 2016;62(7):853-62.
Treasure GC, Aga E, Bosch RJ, et al. "Brief Report: Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials." J. Acquir. Immune Defic. Syndr.. 2016;72(3):310-3.
Henrich TJ, Hanhauser E, Harrison LJ, et al. "CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy." J. Infect. Dis.. 2016;213(5):766-70.
Judge CJ, Sandberg JK, Funderburg NT, et al. "CD14brightCD16- monocytes and sCD14 level negatively associate with CD4-memory T-cell frequency and predict HCV-decline on therapy." J. Acquir. Immune Defic. Syndr.. 2016.
Dirajlal-Fargo S, Moser C, Brown TT, et al. "Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s." Open Forum Infect Dis. 2016;3(3):ofw174.
Kelesidis T, Moser C, Stein JH, et al. "Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s." J. Infect. Dis.. 2016.
Kelesidis T, Tran TTien T, Brown TT, et al. "Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s." Antivir. Ther. (Lond.). 2016.
Robbins GK, Cohn SE, Harrison LJ, et al. "Characteristics associated with virologic failure in high-risk HIV-positive participants with prior failure: a post hoc analysis of ACTG 5251." HIV Clin Trials. 2016;17(4):165-72.
Balagopal A, Gupte N, Shivakoti R, et al. "Continued Elevation of Interleukin-18 and Interferon-γ After Initiation of Antiretroviral Therapy and Clinical Failure in a Diverse Multicountry Human Immunodeficiency Virus Cohort." Open Forum Infect Dis. 2016;3(3):ofw118.
Riddler SA, Aga E, Bosch RJ, et al. "Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy." J. Infect. Dis.. 2016;213(4):556-60.
Girouard MP, Sax PE, Parker RA, et al. "The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States." Clin. Infect. Dis.. 2016;62(6):784-91.

Pages